Syndax Pharmaceuticals, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Syndax Pharmaceuticals, Inc. (SNDX) reported Cash and Cash Equivalents, Period Increase (Decrease) of $11.32 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-08
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $14.44M, a 30.16% increase year-over-year.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$2.26M.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $632.00K.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$1.49M, a 18700.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $11.32M, a 1602.86% increase from fiscal 2016.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $665.00K, a 94.95% decline from fiscal 2015.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $13.17M.
- Syndax Pharmaceuticals, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was -$95.00K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $14.44M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $12.18M derived: sum of 2 quarters · filed 2018-03-08 | $12.81M derived: sum of 3 quarters · filed 2018-03-08 | $11.32M 10-K · filed 2018-03-08 |
| 2017-09-30 | -$2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$1.62M derived: sum of 2 quarters · filed 2017-11-08 | -$3.11M 10-Q · filed 2017-11-08 | $7.98M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $632.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$856.00K 10-Q · filed 2017-08-10 | $10.23M derived: sum of 3 quarters · filed 2018-03-08 | $8.55M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | -$1.49M 10-Q · filed 2017-05-09 | $9.60M derived: sum of 2 quarters · filed 2018-03-08 | $7.92M derived: sum of 3 quarters · filed 2018-03-08 | -$831.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $11.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $9.40M derived: sum of 2 quarters · filed 2018-03-08 | $657.00K derived: sum of 3 quarters · filed 2018-03-08 | $665.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | -$1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$10.43M derived: sum of 2 quarters · filed 2017-11-08 | -$10.43M 10-Q · filed 2017-11-08 | -$41.46M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$8.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$8.74M 10-Q · filed 2017-08-10 | -$39.77M derived: sum of 3 quarters · filed 2018-03-08 | $7.69M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $8.00K 10-Q · filed 2017-05-09 | -$31.03M derived: sum of 2 quarters · filed 2018-03-08 | $16.44M derived: sum of 3 quarters · filed 2018-03-08 | $13.90M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$31.04M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $16.43M derived: sum of 2 quarters · filed 2018-03-08 | $13.90M derived: sum of 3 quarters · filed 2018-03-08 | $13.17M 10-K · filed 2018-03-08 |
| 2015-09-30 | $47.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $44.93M derived: sum of 2 quarters · filed 2016-11-14 | $44.20M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | -$2.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$3.26M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | -$727.00K 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | -$95.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |